Patisiran (Onpattro)

Patisiran (Onpattro) coverage for adults with hereditary transthyretin‑mediated amyloidosis (hATTR) when used per FDA‑approved labeling. Key requirements include confirmatory genetic testing and evidence of amyloid deposition for hATTR with polyneuropathy (typically PND ≤ IIIb or FAP Stage 1–2), prohibition of concurrent use with other TTR‑reducing agents, exclusion for NYHA class III/IV heart failure and post‑liver transplant patients, and 12‑month authorization with continuation dependent on documented clinical stability or improvement.

"For HCSC members residing in Ohio, coverage of any FDA‑approved drug when prescribed for a use recognized as safe and effective in one or more standard medical reference compendia adopted by HHS."

Sign up to see full coverage criteria, indications, and limitations.